CMRX - キメリックス （Chimerix Inc.） キメリックスCMRXのチャート
CMRXの企業情報
| symbol | CMRx |
|---|---|
| 会社名 | Chimerix Inc. （キメリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 チメリックス（Chimerix Inc.）はバイオ医薬品会社である。同社は未充足の医療ニーズに対処する薬品の発見、開発、商業化を行う。同社のリード化合物brincidofovirは天然痘、アデノウイルス（AdV）、およびヒトヘルペスウイルスを含むデオキシリボ核酸（DNA）ウイルスの治療と予防のための経口および静脈内（IV）製剤として開発中である。同社はノロウイルスの予防、治療ためのCMX521の開発を進める。さらに、同社は治療法の乏しいあるいはないウイルス標的に集中するアクティブな発見プログラムがある。Brincidofovirは人間に感染できる5つのファミリーの二本鎖デオキシリボ核酸（dsDNA）ウイルスすべてに対してスペクトル抗ウイルス活性を示した研究用経口ヌクレオチド類似体である。brincidofovirの経口、IV製剤は活性な抗ウイルスをウイルス複製部位に直接送達する開発階段中である。 キメリックスは、米国のバイオ医薬品会社。経口抗ウイルス薬を発見、開発、商品化する。同社は独自の脂質技術を利用し、2種類のヌクレオチド化合物を開発。「Brincidofovir (CMX001)」は第3相臨床段階にある。「CMX157」は第1相臨床試験を終えた後、メルク・シャ―プ・アンド・ド―ム社へライセンス供与した。 Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC. |
| 本社所在地 | 2505 Meridian Parkway Suite 100 Durham NC 27713 USA |
| 代表者氏名 | Martha J. Demski マーサ・J・デムスキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-806-1074 |
| 設立年月日 | 36617 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 82人 |
| url | www.chimerix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cmrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.05300 |
| 終値（lastsale） | 3.84 |
| 時価総額（marketcap） | 184420899.84 |
| 時価総額 | 時価総額（百万ドル） 172.89460 |
| 売上高 | 売上高（百万ドル） 4.72400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.86840 |
| 当期純利益 | 当期純利益（百万ドル） -74.98900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chimerix Inc revenues increased 13% to $2M. Net loss increased 12% to $38.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 21% to $25.2M (expense) General and administrative increase of 7% to $8.8M (expense). |
CMRXのテクニカル分析
CMRXのニュース
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company 2020/03/20 11:44:59 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection 2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
Chimerix +13% on Q4 beat 2020/02/25 14:43:51 Seeking Alpha
Chimerix (CMRX +13.29%) Q4 results: Revenues: $6.8M (+38.8%). Net loss: ($3.5M) (+76.7%); loss/share: ($0.06) (+79.3%); Quick Assets: $113.5M (-39.1%). Bri
Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update | MarketScreener 2020/02/25 12:01:39 MarketScreener
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on… | February 25, 2020
Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year? 2020/01/03 16:30:08 Zacks Investment Research
Is (CMRX) Outperforming Other Medical Stocks This Year?
Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year? 2020/01/03 16:30:08 Zacks Investment Research
Is (CMRX) Outperforming Other Medical Stocks This Year?
Chimerix Inc (NASDAQ:CMRX) Director Buys $54,600.00 in Stock 2019/11/15 18:37:00 Modern Readers
Chimerix Inc (NASDAQ:CMRX) Director Fred A. Middleton acquired 30,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were acquired at an average price of $1.82 per share, with a total value of $54,600.00. Following the transaction, the director now directly owns 117,523 shares of the company’s stock, valued at $213,891.86. […]
Chimerix (NASDAQ:CMRX) Releases Earnings Results, Beats Estimates By $0.07 EPS 2019/11/08 16:04:19 Modern Readers
Chimerix (NASDAQ:CMRX) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.07, Fidelity Earnings reports. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 35.69%. The firm had revenue of $1.96 million during […]
Robert J. Meyer Purchases 10,000 Shares of Chimerix Inc (NASDAQ:CMRX) Stock 2019/11/08 14:50:50 Modern Readers
Chimerix Inc (NASDAQ:CMRX) Director Robert J. Meyer purchased 10,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were purchased at an average price of $1.58 per share, for a total transaction of $15,800.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at […]
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch 2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
Chimerix Inc (CMRX) CEO Michelle Berrey on Q3 2018 Results - Earnings Call Transcript 2018-11-08
Chimerix Inc (NASDAQ:CMRX) Q3 2018 Earnings Conference Call November 8, 2018 8:30 AM ET Executives Michelle LaSpaluto - Senior Director-Accounting Michelle Berrey - President and Chief Executive Officer Tim Trost - Chief Financial Officer Garrett Nichols - Chief Medical Offic…